Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Taking Vemlidy rather than Viread as prophylaxis against hepatitis B is tied to better markers of kidney and bone health.
Among those who switched their hep B treatment, Vemlidy may also be tied to a higher chance of ALT liver enzyme normalization.
Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.
The experimental drug is apparently safer to bones and kidneys.
Highlights from research presented at the 52nd International Liver Congress in Amsterdam
A 96-week study also found that switching from Viread to Vemlidy led to improvements in liver enzyme levels.
Aging and inflammation have become familiar words in the HIV lexicon, up there with terms like CD4 cells, viral load and antiretrovirals.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.